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Abstract
Purpose Chemotherapy increases survival in breast cancer
patients. Consequently, cerebral metastases have recently
become a significant clinical problem, with an incidence of
30–40% among breast carcinoma patients. As this phenom-
enon cannot be studied longitudinally in humans, models
which mimic brain metastasis are needed to investigate its
pathogenesis. Such models may later be used in experimen-
tal therapeutic approaches.
Material and methods/results We report a model in which
69% of the animals (9/13 BALB/c nude mice) developed MR-
detectable abnormal masses in the brain parenchyma within
a 20 to 62-day time window post intra-carotid injection of
435-Br1 human cells. The masses detected in vivo were either
single (7 animals) or multiple (2 animals). Longitudinal MR
(MRI/MRS) studies and post-mortem histological data were
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correlated, revealing a total incidence of experimental brain
metastases of 85% in the cases studied (11/13 animals). ADC
maps perfectly differentiated edema and/or CSF areas from
metastasis. Preliminary MRS data also revealed additional
features: decrease in N -acetyl aspartate (NAA) was the first
MRS-based marker of metastasis growth in the brain (micro-
metastasis); choline-containing compounds (Cho) rose and
creatine (Cr) levels decreased as these lesions evolved, with
mobile lipids and lactate also becoming visible. Furthermore,
MRS pattern recognition-based analysis suggested that this
approach may help to discriminate different growth stages.
Conclusions This study paves the way for further in vivo
studies oriented towards detection of different tumor pro-
gression states and for improving treatment efficiency.
Keywords Brain metastasis · Breast cancer · Proton
magnetic resonance spectroscopy · Magnetic resonance
imaging · Pattern recognition
Abbreviations
ADC Apparent diffusion coefficient
ASCII American Standard Code for Information
Interchange
CBF Cerebral blood flow
CBV Cerebral blood volume
CE-T1 MRI Contrast-enhanced T1 MRI
DAB Diaminobenzidine
DMEM/F12 Dulbecco’s Modified Eagle Medium with
nutrient mixture F12 Ham
d_PI Days post-injection
DWI Diffusion weighted imaging
FBS Fetal bovine serum
FOV Field of view
GFP Green fluorescent protein
GUI Graphical user interface
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H&E Hematoxylin–eosin
IHC Immunohistochemistry
ic Intracarotid
ip Intraperitoneal
LB Line broadening
HBSS Hanks’ balanced salt solution
1H MRS Proton magnetic resonance spectroscopy
ML Mobile lipids
MRI magnetic resonance imaging
MTX Matrix size
MSME multi-slice multi-echo
NEX Number of averages
OCT Tissue freezing medium
PCNA Proliferating cell nuclear antigen
PRESS Point resolved spectroscopy
RARE Rapid acquisition by relaxation enhancement
sc Subcutaneous
SNR Signal to noise ratio
SPF Specific pathogen free
TAT Total acquisition time
TE Echo time
TR Repetition time
VAPOR Variable pulse power and optimized
relaxation delays
ν1/2 MRS peak width at half height
 Big delta
δ Small delta
Introduction
Breast cancer is the leading cause of death in women between
the ages of 35 and 55 [1]. At this age range, breast cancers are
also very prone to metastasize to lymph nodes, bone, liver,
lungs and brain [2,3]. About 30–40% of patients with dis-
seminated breast carcinoma develop metastasis in the CNS,
15% of which with a median survival of 1 year [4] despite
the standard treatment. In fact, the metastasis of breast can-
cer to either the brain parenchyma or the leptomeninges is
generally a late feature of metastatic disease.
Metastasis is a complex multistep process [5] which can
be studied both in vitro, using molecular biology techniques,
and in vivo. As these pathologies cannot be studied longi-
tudinally in humans, due to evident ethical reasons, in vivo
follow-up studies require animal models that can accurately
recapitulate the process observed in humans.
There is abundant information on animal models of pri-
mary breast cancer, e.g. based on the injection of tumor cells
in the mammary fat pad [6]. However, models which mimic
brain metastasis are needed to help understanding this path-
ogenesis and for use in experimental therapeutic approaches.
In 1988, Schackert and Fidler described an animal model of
brain metastasis based on the intracarotid (ic) injection of
human cell lines in nude mice [7]. They used this model to
characterize melanoma brain metastasis and different types
of carcinoma [8]. The same model has already been used in
immunohistochemical studies of different cell lines [9] and
also to study in vivo melanoma brain metastasis by magnetic
resonance imaging (MRI) [10]. More recently, MRI has been
used with another mouse model of human brain metastasis
[11] to track single metastatic cells in the brain [12].
The MRI and MR spectroscopy (MRS) are two powerful
non-invasive techniques that are normally available at any
medical center equipped with a clinical MR scanner. MRI
provides structural characterization of brain tissue, e.g. by
T2 weighted and CE-T1 images. It can also be used to mea-
sure parameters of biophysical interest (to calculate ADC
values, measure CBF and CBV, etc.). In contrast, MRS can
provide biochemical information, i.e. the metabolomic pro-
file in specific regions of the brain (volumes of interest, VOI)
[13–15]. Although both techniques are complementary, nor-
mally only MRI is used in hospitals as a routine tool for brain
tumor diagnosis and prognosis. Therefore, it appears that the
clinical MRS performance needs to be improved. To achieve
this, normalized acquisition and post-processing protocols
should be established. In addition, robust decision support
systems (DSS), which can help in the pattern classification
of spectra [16], should be developed and implemented.
The main objective of this study was to optimize a longi-
tudinal MRI/MRS method for analyzing pathogenic aspects
of brain metastasis growth. This method could be used to
monitor metabolic changes during metastasis development
and therapy response. Accordingly, we have characterized
in vivo the morphologic and metabolic development pattern
of brain metastases induced in nude mice by ic injection of
435-Br1 human mammary carcinoma cells, a brain metasta-
sis variant of the MDA-MB-435 parental cell line (435p in
short) [17]. For this, we used different MRI approaches (T2
and CE-T1 weighted images and diffusion imaging) and 1H
MRS (at both short and long echo times, TE). MRI data was
then compared with the post-mortem histological analysis of
the dissected brains. MRS data was used in a preliminary and
tentative pattern classification attempt of the different pro-
gression stages observed, using a DSS developed for human
brain tumors.
Materials and methods
Cells and animals
Both 435-Br1 human mammary carcinoma cells, originally
established from a brain metastasis in a nude mouse ortho-
topically inoculated with the parental cell line (435p), and
435p/GFP cells, from a parental cell line transfected with
the pCEP4 expression vector containing the GFP (Invitro-
gen, San Diego, CA, USA) [18], were used in this work.
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These were maintained under standard conditions in 1:1 (v/v)
mixture of DMEM and Ham F12 medium, DMEM/F12 (Life
Technologies, Inc. Gibco BRL, Gaithersburg, MD), supple-
mented with 10% fetal bovine serum (FBS), 1 mM pyru-
vate, and 2 mM l-glutamine in a 5% CO2 environment at
37◦C using a humidified incubator [17]. For BALB/c nude
mice inoculation, 435-Br1 cells in exponential growth phase
were first treated with Trypsine-EDTA (Life Technologies)
for 1 min at room temperature. They were then washed twice
in HBSS and counted using a Neubäuer chamber. Viabil-
ity was always between 90 and 97%, as measured by Try-
pan-Blue exclusion. 435-Br1 cells were then resuspended in
HBSS to obtain a final concentration of 1×106cells /100 µl
(aliquot used for inoculation).
Thirteen female 22–24 g athymic BALB/c nude mice
(Charles-River, France) were used in this study of brain
metastasis induction. Animals were housed at the IDIBELL
animal facility in SFP conditions, at 20–24◦C cage tempera-
ture, 60% relative humidity, 12–12 h light–dark periods, and
were allowed free access to UV irradiated water and an ade-
quate sterile diet. Control experiments were performed with
two female 30–40 g CD1 mice (Charles-River), as described
in next section.
Induction of brain metastasis
Brain metastases were generated by inoculation of
1×106435-Br1 cells (resuspended in 100 µl HBSS) into the
internal carotid artery of thirteen mice, using a slight modi-
fication of a previously described method [7]. Briefly, mice
were anesthetized intraperitoneally (ip) with ketamine/xyla-
zine (100/10 mg/kg) and placed supine under a dissecting
microscope. After the right carotid artery was exposed, the
common carotid was permanently clamped with 5.0 suture
silk proximal to the injection point. Both the external carotid
and the occipital branch were temporarily clamped with 7.0
silk suture. A 34G Hamilton needle (Bonaduz, Switzerland)
was then used to deliver 1×106 cells into the internal caro-
tid lumen. At approximately 20 s post-injection, the suture
clamping both the external carotid artery and the occipital
branch was removed. This procedure took about 1 h per ani-
mal and was performed in sterile conditions (laminar flux
cabin) near a dry heat source to prevent body temperature of
the animal from dropping during anesthesia. Following sur-
gery, animals received 20 ml/kg subcutaneous (sc) isotonic
glucosaline solution (0.9% NaCl, 5% glucose) to avoid dehy-
dration and 0.2 mg/kg of buprenorphine (analgesia), both
administered for the following 2 days. When mice presented
visible signs of cachexia, due to metastasis growth, or other
physical evidence of pain and suffering, they were sacrificed
by injection of pentobarbital, 200 mg/kg, 60 mg/ml. This pro-
cedure was approved by the lDIBELL, UAB and IIB Animal
Healthcare Committees.
To optimize surgical conditions, we used two CD1 mice
inoculated with 1×106 in 50 µl 435p/GFP cells injected into
the right internal carotid artery. In order to monitor the loca-
tion of the injected cells in the central nervous system [19]
at different time points, one animal was sacrificed at 5 min
post-inoculation while the other one was sacrificed right after
the inoculation, both with the CO2-breathing method. The
brains were then removed and fixed for histological analyses
as explained in the “histological analysis” section.
In vivo set-up
In vivo MR studies were carried out on a high-field horizon-
tal spectrometer (Bruker PharmaScan 7.0 Tesla, Ettlingen,
Germany) equipped with actively shielded gradients (300
mT/m) and a 23 mm diameter birdcage resonator specially
designed for mouse head studies. Anesthesia was performed
using isoflurane at 1–2.5% in O2, maintaining the respira-
tory frequency between 40 and 60 breaths/min, as monitored
by BioTrigg equipment (Bruker). Animal body temperature
was maintained using a heated water blanket. Tumors were
studied by MRI/MRS as described in the next section.
MRI acquisition and post-processing
Animals were studied by T2, CE-T1 and diffusion weighted
imaging (DWI). Single-voxel proton spectroscopy
(1H-MRS) was also used at two echo times (TE: 35 and
136 ms), as described in more detail in the next section.
For this, the voxel was always positioned inside the brain
parenchyma and centered in or around the abnormal mass
detected by MRI; in the case of longitudinal studies, voxel
positions were reproduced as well as possible (visual confir-
mation). All MR studies were performed at the SIERMAC
(NMR facility of the Instituto de Investigaciones Biomédi-
cas “Alberto Sols”, UAM-CSIC, Madrid, Spain), according
to protocols approved by the local animal healthcare com-
mittee for animal handling in MR experiments.
Acquisition parameters for T2-W MRI were as follows:
RARE sequence (turbo factor, 8); field of view (FOV),
20×20 mm; matrix (MTX), 256×256 (78×78µm/pixel);
number of slices (NS), 14; slice thickness (ST), 1 mm; inter-
slice distance (ISD), 1.1 mm; TR/TE, 2,500/60 ms; number
of averages (NEX), 4; total acquisition time (TAT), 5 m 20 s.
Acquisition parameters for CE-T1 MRI (Gd-DTPA bolus
injection in the tail vein at 0.2 mmol/kg previous to MR acqui-
sition): MSME sequence; FOV, 20×20 mm; MTX, 256×256
(78×78µm/pixel); NS, 14; ST, 1 mm; IST, 1.1 mm; TR/TE,
350/11.5 ms; NEX, 4; TAT, 5 m41 s. The volume rendering
of tumor masses detected in CE-T1 images was obtained by
post-processing as follows: abnormal mass(es) were high-
lighted in each image of the T1 sequence using a manually
defined region of interest (ROI) for each individual mass.
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The given areas for each ROI were then added and multiplied
by the inter-slice distance. This process was performed using
Image-J software [20]. Acquisition parameters for DWI were
as follows: Stejskal-Tanner sequence, one gradient for diffu-
sion (read); 3 b values (100, 400, 800 s/mm2); /δ,
8.52/5.00 ms; FOV, 20×20 mm; MTX, 128×128 (156×156
µm/pixel); NS, 6; slice thickness, 1 mm; IST, 1.1 mm; TR/TE,
3,000/20 ms; NEX, 1; TAT, 19 m15 s. The images obtained
were then processed to generate ADC maps with interactive
data language (IDL) home written software [21].
MRS acquisition and post-processing
1H-MRS acquisition parameters were as follows: PRESS
sequence with VAPOR for water suppression; voxel volume,
3×3×3 mm (27µl); TR/TE, 3,000/35 or 136 ms (short and
long TE, respectively); number of scans (NS), 128; TAT,
6 m5 s; receiver gain (RG), constant value (40,000). Spec-
tra were then processed using MestReC software [22]: zero
filling of 4,096 to 8,192 points, 1, 3 or 7 Hz line broadening
(for ν1/2 measurement of non-suppressed water peaks and
metabolite peaks in water-suppressed spectra and displayed
spectra, respectively) and zero order phase correction. For
the spectral analysis, absolute intensity values were depicted
for the peaks of interest. A prototype version of a DSS devel-
oped for pattern recognition of human brain tumor spectra,
SV INTERPRET v1.2 [23,24], was used to tentatively fol-
low the pattern evolution of spectra acquired at short and
long TEs in a longitudinal study of metastasis progression.
To attain this, the ASCII format of each spectrum (obtai-
ned with MestRe-C) was normalized to unit length using the
following formula (strategy already applied to human brain
tumor data analyzed for the DSS development [16]):
Inorm i = Ireali√∑7.1
ppm=−2.7 Ireali2
(1)
Inorm and Ireal refer to the intensities at each data point in
the normalized spectra and in the real part of the acquired
spectra, respectively. Subsequently, the normalized ASCII
file was fed into the DSS and evaluated as described in [24].
Histological analysis
Mice brains were fixed after sacrifice in 4% paraformalde-
hyde for 24 h, followed by 30% sucrose for another 24 h.
The tissue was then OCT-embedded (tissue freezing medium,
Sakura Tissue-Tek)before being frozen in dry ice. Samples,
which were kept at −80◦C, were cut into 5 µm coronal sec-
tions for evaluation (cryostate at −27◦C). In immunofluo-
rescence control studies (CD1 mice), sections were directly
analyzed on a fluorescence microscope (Olympus IX70) with
two filters:one for visible light (morphological analysis) and
one for fluorescence (GFP-labeled tumor cell detection). In
MR longitudinal cases (nude mice), metastatic involvement
was explored in each section after classic hematoxylin–eosin
(H&E) staining.
The proliferation state of metastasis was assessed by
immunohistochemistry (IHC) using specific PCNA (prolifer-
ating cell nuclear antigen) antibody sc-56 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), clone PC10 at 1:50
dilution (PBS–BSA 2% solution incubated overnight at 4◦C).
A biotinylated anti-mouse secondary antibody diluted in
PBS-BSA 2% at 1/2,000 (Pierce, Perbio Science Ltd.,
Cheshire, UK) was incubated for 30 min at room temperature,
following DAB (diaminobenzidine) staining and counter-
staining with hematoxylin. IHC were visualized on an
Olympus BX60 microscope (Olympus Optical Co., LTD,
Japan) and digitalized with a camera and using the Spot 4.2
software (Diagnostic Instruments, Inc, Sterling Heights, MI,
USA). For each sample, three fields containing 200 cells were
counted for positive PCNA cells (results shown in results sec-
tion as average percentage).
Results
Control fluorescence studies
Fluorescence histological analysis from two CD1 mouse
brains (previously inoculated with 435-Br1/GFP cells and
sacrificed at 0 and 5 min post-injection), showed cells in the
lumen of parenchymatous microvessels in both cases, reveal-
ing that they had reached the brain parenchyma microvessels,
as expected (Fig. 1a).
MRI and histological analysis
Approximately 2 weeks after injection of 435/Br-1 cells in
nude mice, animals recovered their original weight and MR
monitoring was started. Longitudinal MRI/MRS studies were
performed in mice up to 32– 92 days post-injection of cells,
days_PI (except for the case of Nude 2, studied for 265 days).
The number of explorations carried out ranged between 1 and
6, depending on the availability of spectrometer time and
overall survival of the animals investigated. T2 and CE-T1
weighted images were used to detect metastasis and localize
them in the brain parenchyma. Metastases were first detec-
ted between 20 and 62 days post-injection in different brain
regions for each afflicted animal (Nude 1, 5, 6, 7, 9, 11, 13:
hypothalamus; Nude 3: cerebellum-right hemisphere region;
Nude 8:cortex, hippocampus, ventricle, frontal lobe and
hypothalamus). This is summarized in Table 1.
In some animals, tumor masses were found in other regions
of the body besides the brain. These included the right jaw
(7 animals, 6 also with a brain tumor detected) and soft tis-
sue in the neck (1 animal: Nude 10). Tumors detected in
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Fig. 1 a Histological analysis of CD1 mouse brain: animal sacrificed 5
min post-i.c. inoculation of 435-Br1 human breast cancer cells transfec-
ted with GFP (435-Br1/GFP). Injected tumor cells reached the cerebral
parenchyma microvessels (white arrow): (I) fluorescent signal from
cells (bright green over a darker background); (II) capillary morphol-
ogy in brain parenchyma, same slice as in “I” but using visible light.
Images: 20 µm thickness/40 × enlargement. b Longitudinal studies of
tumor progression using CE-T1. Metastases are seen in coronal sections
as bright spots inside the brain parenchyma. Nude 3: images obtained at
days 26, 33 and 40 post-injection (d_PI) from top to bottom; metastasis
first detected at d26_PI as a single mass (highlighted by yellow arrow).
Nude 8: coronal sections obtained at days 44, 58 and 65 PI; metastasis
first detected at d44_PI as multiple masses that infiltrate through the
brain parenchyma (two highlighted by a yellow arrow). C post-mortem
histology studies. Nude 8 at d65_PI. Top: CE-T1 MRI coronal section
(left) obtained in vivo from the position highlighted below and post-
mortem hematoxylin–eosin (H&E) staining of a 5µm slice from that
region (insert at right, 10 × magnification). Bottom: four transversal
sections (1–4, anterior to posterior) obtained by CE-T1 MRI
the jaw (28–38 days_PI), normally evolved rapidly, causing
feeding problems in the afflicted animals. This eventually led
to ending the MR studies before brain tumor masses could
be further monitored (in 5 cases: Nudes 3, 7, 8, 9, 11) or even
detected (Nude 12). Furthermore, we cannot discard effects
of repeated and long-term anesthesia contributing to death in
6 of the 13 cases studied (Nudes 1, 2, 4, 5, 6 and 13).
Figure 1b shows two examples of longitudinal studies
at different days post-injection of metastatic cells. The
growth of brain metastases is well observed in both cases,
either as one localized mass whose size increased with
time (Nude 3), or as multiple masses that spread over
the brain parenchyma (Nude 8). Post-mortem histological
analyses in transversal and coronal slices were carried
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Table 1 Summary of first detection of in vivo brain and jaw metastases for each BALB/c nude mouse at different days post-injection of 435-Br1
cells (d_PI)
Mouse (Nude) MR monitoring Death Histology
(#) (Metastasis, d_PI) (d_PI) (Metastasis, Yes/No)
Hyp Jaw uBP Brain Lung Liver
1 5 35 28 – 54b
2 4 – – – 265b Yes No No
3 3 26 – 26 42 Yes No No
4 3 – – – 45a No Yes No
5 1 20 – – 32b
6 8 62 – 62 92 Yes No No
7 4 46 30 46 51 Yes Yes No
8 6 30 37 37 61 Yes Yes No
9 3 48 31 48 52 Yes No No
10 2 – – – 48 Yes Yes No
11 1 38 38 – 50 Yes Yes No
12 3 – 34 – 45 No Yes No
13 1 27 27 – 36a
“#”, number of MR explorations per animal; uBP, upper brain parenchyma; Hyp, hypothalamus; “–”, metastasis no detected. With respect to death
(time shown as d_PI), animals were sacrificed because of symptoms or, in some cases, died during the MR exploration (a) or while recovering from
anesthesia (b). Metastases presence in the brain, lung and liver, as detected by post-mortem histological analysis, is also summarized for the cases
studied (“empty cells”, sample not available)
out in most cases to confirm the extension of the disease
(Fig. 1c).
CE-T1 images were further used for volume rendering of
metastasis at each progression stage (Fig. 2a). This enabled us
to determine growth kinetics curves for each afflicted animal.
Each time series was adjusted to a polynomial function (lin-
ear when only two points were available). When taken toge-
ther, this allowed us to generate an average growth curve, as
shown in Fig. 2b. Thus, 69% of the animals (9/13 mice) devel-
oped MR-detectable abnormal masses in the brain paren-
chyma within a 20–62 days time window PI. These masses
were either single (7 animals) or multiple (2 animals).
Diffusion weighted images (DWI) were also acquired.
Only one diffusion axis gradient was used (Gread), assum-
ing for the calculations an isotropic diffusion in metastatic
regions. The DWI were used to generate apparent diffu-
sion coefficient (ADC) maps in different coronal slices from
neck to snap (Fig. 3). Metastatic regions in the brain paren-
chyma (color coded in green) had higher ADC values
than non-afflicted tissues (blue color): 0.88 ± 0.07 vs.
0.54 ± 0.05×103 mm2/s, respectively, for the example cases
shown. Furthermore, ADC maps perfectly differentiated
edema and/or CSF areas (bright regions shown in T2 brain
images and color coded in green–yellow–red in ADC maps)
from metastases.
Correlation of in vivo MRI analysis with post-mortem
histology results of sequential coronal tumor sections was
performed for the fixed brains of 10 of the 13 cases studied
(3 samples could not be used for histological analysis pur-
poses). These included 6 of the 9 MRI-detected metastases
cases (Fig. 4), which presence was confirmed in all cases.
Occurrence of metastases was also confirmed in 2 of the 4
non MRI-detected metastases cases. Altogether, in vivo and
post-mortem data indicates occurrence of metastases in 11 of
13 animals studied (85% incidence). Histology results also
indicate lung metastasis presence in 6 cases (4 with brain
metastasis), not (yet) affecting the lobules in any of the stud-
ied cases, while no liver metastases were detected in any case.
The jaw masses seen in vivo were confirmed (for one case)
as metastases.
Additional PCNA analysis in 20 µm slides showed some
heterogeneity in the proliferation pattern of these metastases,
particularly when comparing masses seen in hypothalamus
(Hyp) with those detected in the upper brain parenchyma
(uBP)—Nude 3 (Fig. 4a): 82% of PCNA positive cells (Hyp);
Nude 8 (Fig. 4b): 40% (uBP), 29% (uBP) and 15% (Hyp);
Nude 9 (Fig. 4c): 79% (uBP) and 65% (Hyp).
MRS
The MRS was conducted in a total of 10 animals, 8 of which
harboring brain metastases. This was performed by single
voxel 1H-MRS, at short and long TE (35 and 136 ms, respec-
tively). Due to field homogeneity problems and/or difficul-
ties in fitting the metastasis region(s) inside the voxel (e.g.,
masses in hypothalamus), the metabolic pattern of these
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Fig. 2 a Protocol used for
volume rendering of abnormal
masses found inside the brain
parenchyma. b Metastasis
growth patterns (volume in µl)
inside the brain parenchyma at
different days post-detection
(PD) for nine animals (fitting
curves shown as dotted lines):
three animals with single point
MR monitoring (no fitting) —
Nude 5, Nude 11 and Nude 13;
two cases with 2-point MR
monitoring (linear
fitting)—Nude 7 and Nude 9
(shown with more detail on the
enlarged region displayed as an
insert in the upper part of the
plot); four cases with more than
2 points (squared polynomial
fitting, r2 = 0.99 − 1)—Nude 1,
Nude 3, Nude 6 and Nude 8. The
average growth curve for the
monitored masses was
calculated from all the fitting
curves and was also fitted to a
squared polynomial function
(solid line error bars, ±SD) to
calculate the average tumor
duplication time (4–5 days after
first detection), r2= 1
lesions was analyzed in detail in only two cases. As shown in
Figs. 5 and 6, good quality spectra were obtained (Nudes 7
and 8—SNR for the tallest resonance in the spectral range of
4.5 – 0.0 ppm: 36–70), with ν1/2 generally around 18–20 Hz
for both the non-suppressed water (LB= 1 Hz) and metabo-
lite peaks (creatine was used as a reference, LB=3 Hz).
As shown in Fig. 5a, where the apparent tumor volume
for Nude 7 was only 0.74% and 2.2% of the total voxel vol-
ume used (27 µl) at days 46 and 51 post-injection of cells,
respectively, there was some decrease in NAAwhile Cho and
Cr levels did not seem to be affected: Fig. 5b, c (a small
increase in Cho and Cr was observed, although we cannot
rule out here an effect of voxel repositioning in those minor
changes). In the 5-week longitudinal study shown in Fig. 6,
the spectral changes clearly indicate that, as the tumor vol-
ume sampled by the voxel increases, there is a decrease in
both N -acetyl aspartate (NAA) and creatine (Cr) peak heights
and an increase in choline containing compounds (Cho) and
mobile lipids (ML) both seen at short TE, as well as lactate
(Lac) detection at long TE.
To complement these qualitative analyses, an evolving
DSS (SV INTERPRET GUI v1.2) [23,24] was used to
tentatively follow the evolution of the spectral pattern detec-
ted in our animal model at both long and short TE, as shown
in Fig. 6. The normalized spectra of the metastatic human
cells growing in nude mice detectable at 7.0 T seem compati-
ble with the human brain tumor patterns obtained at
1.5 T, represented in this DSS. In addition, the evolving pat-
tern of the sampled voxels was concordant with the replace-
ment of normal brain parenchyma (lower right corner of the
GUI display) by aggressive tumor cells (upper right corner
of the GUI).
Discussion
Preliminary characterization of brain metastasis growth
Control fluorescence studies, carried out in the initial exper-
iments with CD1 mice, confirmed from the initial experi-
ments that the inoculation technique was being performed
properly. In our experimental model, brain metastasis pro-
gressed in 69% of the cases (9 of 13 animals studied) within
a 20 to 62-day time window post–injection, as detected
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Fig. 3 T2-W, CE-T1 and ADC maps for the same slices. In Nude
8, different coronal slices obtained from neck to snap (left to right).
ADC maps perfectly differentiate edema and/or CSF areas (seen in
T2-weighed images as brighter areas) from metastasis (regions 5–10,
white numbers seen by CE-T1 also as brighter areas), as regions of
ADC values higher than the normal brain parenchyma regions (1–4).
One metastasis located in the hypothalamus of Nude 6 and Nude 11
is shown in a coronal section both by CE-T1 and ADC maps (regions
12 and 14, respectively). ADC values measured (10−3mm2/s) were:
1, 0.54 ± 0.08; 2, 0.54 ± 0.08; 3, 0.58 ± 0.06; 4, 0.55 ± 0.07; 5, 1.02
± 0.09; 6, 0.84 ± 0.06; 7, 0.9 ± 0.12; 8, 0.92 ± 0.07; 9, 0.88 ± 0.10;
10, 0.88 ± 0.11; 11, 0.56 ± 0.11; 12, 0.81 ± 0.09; 13, 0.45 ± 0.1; 14,
0.79 ± 0.12
in vivo by MR and summarized in Table 1 and Fig. 2b. Metas-
tasis had a heterogeneous distribution when first detected
by MRI experiments. This may be correlated with the ini-
tial entry point of the cells in the brain parenchyma. Thus,
there may be regions where metastatic cells are more prone
to extravasate and invade through the blood brain barrier
(BBB), although further experiments should to be undertaken
to test this assumption. Furthermore, the histological analy-
sis of samples, apart from confirming the metastatic origin
of the in vivo-detected brain masses, revealed that two addi-
tional animals had brain metastasis (Table 1: Nude 2 and
Nude 10). This indicates a total incidence of brain metasta-
sis of 85% among the population studied (11/13). Therefore,
brain micrometastases that were not compromising the BBB
integrity at the time of imaging were not detected in vivo
by CE-T1 MRI, as expected [10]. Accordingly, they could
not be taken into account for MRI-derived volume measure-
ments.
The hypothalamus region seems less prone to allowing
metastatic cells to invade the nearby parenchyma, since
metastasis growth in this region was slow in the different
animals investigated (Fig. 2b, i.e., Nude 6). This may also be
related to the presence of other metastases present in the body
which could perhaps simulate the effect of a primary tumor
that endogenously inhibits the growth of dormant (silent)
brain metastatic cells, as proposed by others [30]. Assum-
ing this possibility, the metastatic masses detected in the
jaw of 7 animals (54%, confirmed by histology in one case),
6 of which with MR-detected brain metastasis, are
potential sources of such effect. These type of lesions, well-
documented in human breast cancer brain metastasis [25–
27] and in animal models [28,29], should have originated
in our case from some of the inoculated cells that reached
the homolateral masticatory muscles through the palatine
branch, which derives from the internal carotid artery just
before the base of the skull. As the hypothalamus-detected
metastases are in close proximity to the circle of Willis, and
all its major arterial branches, they could perhaps be influ-
enced by cytokines from nearby jaw tumors. Therefore, an
endogenous inhibition effect of brain metastasis growth may
explain why the incidence of brain metastases detected here
was lower than that reported in previous work [8], although
additional experiments would be required to confirm this
assumption.
Despite the limitations in the MRI contrast method used,
PCNA proliferation indexes (Fig. 4) correlated positively
with the in vivo growth rates observed in the cases studied at
the time of inspection (although in the case of Nude 9 there
are not enough time point inspections to assure that, Fig. 2b
seems to suggest it). The PCNA expression profiles there-
fore suggest that the proliferation of hypothalamus masses
in mice without jaw metastases (Nude 3, 82% proliferation
index) was higher than in mice with jaw metastases (Nude 8
and Nude 9, 15% and 65% proliferation index, respectively)
and also that hypothalamus masses displayed higher prolifer-
ation arrest as compared to other cerebral metastases present
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Fig. 4 Correlation between in
vivo studies and the
post-mortem analysis of selected
tumor sections (from left to
right): CE-T1, H&E staining
(10 × magnification) and PCNA
nuclear expression to measure
the proliferative status of brain
metastasis (40 × magnification).
a Nude 3, CE-T1 image with the
corresponding H&E section and
82% of PCNA positive cells. b
Nude 8, CE-T1 image with three
different regions analyzed:
sections 1 and 2 with 15 and
29% of PCNA positive cells,
respectively; section 3 with 40%
of positive cells and the
corresponding H&E. c Nude 9,
CE-T1 image with two different
regions analyzed: section 1 with
65% of PCNA positive cells,
and section 2 with 79% of
PCNA positive cells and the
corresponding H&E
(PCNA proliferation index: Nude 8, 29 and 40%; Nude 9,
79%). Nevertheless, a larger animal cohort would be needed
to investigate this possibility.
According to diffusion imaging data (Fig. 3), metasta-
ses had higher ADC values than apparently non-afflicted tis-
sues (0.89 ± 0.07 vs. 0.56 ± 0.02×103 mm2/s, respectively).
This would suggest that these are lesions with relatively low
cellularity, which is in agreement with other literature on
animal models of human tumors [31,32]. Histology studies
confirmed this assumption by demonstrating lower cell pack-
ing in these masses than in surrounding brain parenchyma
(Fig. 4a, H&E), which should allow water to diffuse more
freely.
Regarding MRS monitoring, only cases with good field
homogeneity and correct positioning of the voxel inside the
lesion were further analyzed (i.e., brain metastases located
away from the ear cavities or meninges, which affect shim-
ming due to susceptibility artifacts). Among the 10 cases
investigated by MRS, only 8 had brain metastases and just
2 fulfilled this requirement; the field homogeneity was not
sufficient to produce good quality spectra in 3 cases, while in
other 3 metastases were located in the hypothalamus region
of the brain parenchyma, forcing us to sample only a small
fraction of the lesion which was sufficiently away from to
the ear cavities (voxels containing mostly non-afflicted brain
parenchyma).
Even though large voxels were used (27 µl), relatively
small tumoral masses detected by MRI (micrometastasis
0.2–0.6 µl), along with possibly associated peritumoral
effects from the nearby brain parenchyma included in the
voxel (i.e., edema [33] and vascular changes [10]), seemed
to perturbate the MRS pattern (Fig. 5). In this case, a decrease
of 21% in N-acetyl aspartate (NAA, marker of neuron viabil-
ity) was the first MRS-based sign of early metastasis growth
in the brain. As these lesions increased in size and infiltrated
the brain parenchyma (Fig. 6), the spectral changes seen at
both short and long TE clearly indicate a substitution of the
healthy tissue pattern by a malignant tumor pattern (meta-
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Fig. 5 Longitudinal MRS studies of Nude 7. a Voxel position at each
day of study (d46_PI, red square, and d51_PI, green square) shown
overlaid into CE-T1 coronal sections obtained at each day of inspection
(volume rendering of the metastasis mass gave 0.2 and 0.6 µl, respec-
tively). b Short TE 1H-MRS spectra acquired from the voxels shown in
a. c Absolute intensity of selected peaks, arbitrary units (Cho, 3.21 ppm;
Cr, 3.03 ppm; NAA, 2.03 ppm) at each day PI
static cells): choline-containing compounds (Cho, marker of
cell proliferation) increased while creatine levels (Cr, total
creatine, bioenergetics spatial-temporal buffer) decreased, as
already described in single time point explorations of human
patients [13]. In addition, mobile lipids (ML) were obser-
ved at short TE after a certain period of growth, while lactate
(Lac, a well known marker of an activated glycolitic pathway
in tumors [13]) was detected at long TE, in agreement with
other studies of stereotactically induced murine glial tumors
[34,35]. Comparing the behavior of the ML resonance at
both short and long TE (present and absent, respectively, at
1.3 ppm) we could assume that these ML are mostly located
in small lipid droplets (1–2 µm diameter), which accumulate
inside viable tumor cells [36], and not in big lipid droplets
generally found in necrotic regions [37]. Therefore, metas-
tasis progression seems to occur in this case without major
necrosis in the time frame followed by MR. In the last MRS
analysis shown in Fig. 6, a decrease in Cho and ML at short
TE was found. This may be related to a reduction in tumor
growth rate due to increased tumor size and lack of adequate
perfusion. However, tumoral signaling from the jaw mass
present and/or other metastases in the body (like lung metas-
tases, identified post-mortem in 6 of the cases studied) could
also play a role, according to the “endogenous inhibition
hypothesis” previously referred.
An alternative to the qualitative MRS analysis just descri-
bed (observing the spectral changes of selected peaks) is to
use the complete spectral pattern for classification in tumor
types or grades. To this end, the use of a decision support sys-
tem (DSS) for pattern recognition analysis is required. Here
we show that a DSS developed for human brain tumor spec-
tra, obtained with clinical spectrometers (1.5T) [24] seems
to produce compatible results when used to analyze spec-
tra obtained in our animal model at both short and long TE
(Fig. 6). Even though this classifier is not optimized for our
tumor model, it is still able to track the expected change in
the sampled spectral pattern from mostly normal brain paren-
chyma to mostly aggressive tumor. Furthermore, in the last
progression stage detected by MRS (day 65 post-injection)
the DSS was able to differentiate well the metastasis pattern
(human cells growing in nude mice) from non glial tumors,
such as meningiomas or low grade glial tumors, position-
ing the spectra in the glioblastoma– metastasis region, as
expected.
Additional remarks and future perspectives
The MDA-MB-435 human breast cancer cell lines have ser-
ved as the mainstay of brain metastasis work. They have
been used to produce brain metastases in experimental assays
via infusion into either the carotid artery or the left cardiac
ventricle [6,11]. The tissue of origin has been a matter of
debate since analysis of DNA microarray data indicated that
MDA-MB-435 might be of melanocytic origin, due to their
similarity to melanoma cell lines [38]. However, our results
provide information about the pathogenesis of brain metasta-
sis regardless of the primary tumor location. Another model
described for generating brain metastases in nude mice is
based on intracardiac injection of the cells. This model has
been used to report the occurrence of different metastatic
cell populations in the brain [12]. In this case, at day 28 post-
injection of MDA-MB-431 mammary carcinoma cells, only
1.5% of the initially detected cells (day 0) were proliferat-
ing, while 4.5% remained as solitary non-proliferating cells.
Something similar could also have happened in our work,
where we were limited to conventional T2 and Gd-DTPA CE-
T1 MRI methods for detecting areas of compromised BBB,
thus missing single cell detection [12] or small cellular tumor
masses that had not yet compromised the BBB [10]. As for
MRS, spectroscopy techniques with higher resolution should
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Fig. 6 Longitudinal MRS
studies of Nude 8. a Voxel
position (white squares) shown
in both coronal and transversal
sections of CE-T1 images
obtained at d62_PI. b 1H-MRS
spectra at both short and long TE
(top and bottom, respectively),
acquired from the voxel shown
in a at different days PI (37, 44,
51, 58 and 62, color legend at
the left of the long TE spectra).
c Absolute intensity of selected
peaks, arbitrary units (Cho,
3.21 ppm; Cr, 3.03 ppm; NAA,
2.03 ppm; ML, 1.30 ppm, for
short TE) at each day PI. Lac is
also visible in long TE spectra
(1.32 ppm) at days 58 and 62 PI.
d, e Pattern recognition-based
visualization of normalized
spectra. Normalized MRS
spectra of Nude 8 were entered
into the INTERPRET SV DSS
v1.2 both for short (a) and long
(b) TEs. Each spectrum is
represented by two discriminant
scores (x and y axis) calculated
by a linear combination of
weighted selected peak heights
and visualized as a yellow dot on
the interface (top-left). On the
right, spectra corresponding to
days 37 and 62 PI are shown
(bottom and top, respectively).
Six classification groups are
shown on the interface section
(left): healthy tissue, white;
meningioma, grey; astrocytoma
II, blue; astrocytoma III, green;
glioblastoma multiforme, red;
metastases, pink. The DSS
screen suggests a different
pattern for the metastasis
(human cells growing in nude
mice) from non-glial tumors,
such as meningiomas, and
places the consecutive spectra in
a clear progression towards
malignancy. Initially, the spectra
resemble human cases of
healthy tissue, d51_PI. This is
then replaced by low grade glial
and finally evolves towards an
aggressive pattern
(Glioblastoma/Metastasis),
d62_PI
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be used. This involves increasing voxel resolution by switch-
ing from single-voxel to multi-voxel spectroscopy (chemical
shift imaging), as recently described [39].
Conclusions
The metastasis induction protocol used has demonstrated that
MRI and MRS can be used to follow brain metastasis growth
kinetics, as confirmed by histological analysis. The qualita-
tive agreement between the PCNA-based proliferation rate
and MRI-measured growth kinetics, along with the preli-
minary pattern recognition analysis of a longitudinal MRS
series, opens the way for metastasis growth classification
into distinct progression stages and ultimate correlation with
human brain metastasis diagnosis and therapy response. In
this regard, it is worth considering the potential of the repea-
ted intra-cardiac injection method [11] for further studies. In
addition, more sensitive contrast methods should be used for
in vivo MRI (intracellular or extracellular iron oxide parti-
cles, for single cell detection [12] or as a blood pool agent
[10], respectively). Furthermore, localized multi-voxel spec-
troscopy (chemical shift imaging), already described for the
mouse brain [39], should improve the MRS study of this
model.
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